GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

https://www.news-medical.net/health/GLP-1-receptor-agonists-in-Alzheimere28099s-disease-Emerging-off-label-neuroprotective-potential.aspx From reduced amyloid and neuroinflammation in experimental models to mixed cognitive outcomes in clinical trials, emerging evidence is testing whether GLP-1 receptor agonists can move beyond metabolic therapy to become meaningful treatments for Alzheimer’s disease.